Use of Direct Oral Anticoagulants in UK

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

31336 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-15

Study Completion Date

2019-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it. It is important to prescribe the correct dose of blood thinners to the right patients to ensure the treatment works however avoiding complications. In the recent years, new blood thinners have been available; they require less laboratory tests and fewer visits to a doctor compared to older therapies. This study will look at how the general practitioners in the UK prescribe blood thinners according to the instructions given by the product manufacturer. We will use primary care data that is routinely collected by the general practitioners about their patients but without any possibility to identify individual patients. The results will help us to understand the magnitude of deviation from instructions in order to ensure that the patients benefit from the treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

NCT03568916

Atrial Fibrillation Ischemic Stroke Systemic Embolization +3 more

COMPLETED

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment

NCT04174859

Non-valvular Atrial Fibrillation

COMPLETED

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543

Atrial Fibrillation Percutaneous Coronary Intervention

COMPLETED PHASE3

Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation

NCT02565693

Cerebral Hemorrhage Atrial Fibrillation

COMPLETED PHASE2

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs

NCT04401761

Coronary Artery Disease Peripheral Artery Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stroke Prevention with Rivaroxaban in NVAF Patients

All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type DRUG

Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD

Stroke Prevention with Dabigatran in NVAF Patients

All NVAF patients above 18 years for age prescribed with Dabigatran during the study period

Dabigatran

Intervention Type DRUG

Oral direct thrombin inhibitors, 75mg and 150mg capsules BID

Stroke Prevention with Apixaban in NVAF Patients

All NVAF patients above 18 years for age prescribed with Apixaban during the study period

Apixaban

Intervention Type DRUG

Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban (Xarelto, BAY59-7939)

Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD

Intervention Type DRUG

Dabigatran

Oral direct thrombin inhibitors, 75mg and 150mg capsules BID

Intervention Type DRUG

Apixaban

Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients aged \>= 18 years with at least one year of enrollment with the primary care practice and one year since first health contact recorded in the database THIN(The Health Improvement Network) or CPRD(Clinical Practice Research Datalink) prior to index prescription date will be included.
* Patients with first prescription of DOACs (rivaroxaban, dabigatran, apixaban) during the study period.
* Diagnosis NVAF (any time prior index date or within the 2 weeks after the index date)

Exclusion Criteria

* Patients having the history of valvular replacement or mitral stenosis (prior to index date or 2 weeks after index-date)
* Patients who have any record of being prescribed their index drug prior to the enrolment period or who qualify as members of more than one cohort on the same day.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No